First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report

A 90‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death‐ligand 1 (PD‐L1) was highly expressed with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamai, Kosuke, Tanahashi, Hiroki, Ueno, Sayaka, Konishi, Hanae, Matsumura, Mirai, Nomura, Akio, Nakamoto, Kanako, Isoyama, Shoko, Tanimoto, Takuya, Shoda, Hiroyasu, Ishikawa, Nobuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262880/
https://www.ncbi.nlm.nih.gov/pubmed/32291904
http://dx.doi.org/10.1111/1759-7714.13436
_version_ 1783540705988182016
author Hamai, Kosuke
Tanahashi, Hiroki
Ueno, Sayaka
Konishi, Hanae
Matsumura, Mirai
Nomura, Akio
Nakamoto, Kanako
Isoyama, Shoko
Tanimoto, Takuya
Shoda, Hiroyasu
Ishikawa, Nobuhisa
author_facet Hamai, Kosuke
Tanahashi, Hiroki
Ueno, Sayaka
Konishi, Hanae
Matsumura, Mirai
Nomura, Akio
Nakamoto, Kanako
Isoyama, Shoko
Tanimoto, Takuya
Shoda, Hiroyasu
Ishikawa, Nobuhisa
author_sort Hamai, Kosuke
collection PubMed
description A 90‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death‐ligand 1 (PD‐L1) was highly expressed with a tumor proportion score (TPS) of >75%. Pembrolizumab therapy in the first‐line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with both EGFR mutation and high expression of PD‐L1 are very rare.
format Online
Article
Text
id pubmed-7262880
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-72628802020-06-01 First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report Hamai, Kosuke Tanahashi, Hiroki Ueno, Sayaka Konishi, Hanae Matsumura, Mirai Nomura, Akio Nakamoto, Kanako Isoyama, Shoko Tanimoto, Takuya Shoda, Hiroyasu Ishikawa, Nobuhisa Thorac Cancer Case Reports A 90‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death‐ligand 1 (PD‐L1) was highly expressed with a tumor proportion score (TPS) of >75%. Pembrolizumab therapy in the first‐line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with both EGFR mutation and high expression of PD‐L1 are very rare. John Wiley & Sons Australia, Ltd 2020-04-14 2020-06 /pmc/articles/PMC7262880/ /pubmed/32291904 http://dx.doi.org/10.1111/1759-7714.13436 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Hamai, Kosuke
Tanahashi, Hiroki
Ueno, Sayaka
Konishi, Hanae
Matsumura, Mirai
Nomura, Akio
Nakamoto, Kanako
Isoyama, Shoko
Tanimoto, Takuya
Shoda, Hiroyasu
Ishikawa, Nobuhisa
First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report
title First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report
title_full First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report
title_fullStr First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report
title_full_unstemmed First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report
title_short First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report
title_sort first‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both egfr mutation and high expression of pd‐l1: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262880/
https://www.ncbi.nlm.nih.gov/pubmed/32291904
http://dx.doi.org/10.1111/1759-7714.13436
work_keys_str_mv AT hamaikosuke firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT tanahashihiroki firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT uenosayaka firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT konishihanae firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT matsumuramirai firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT nomuraakio firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT nakamotokanako firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT isoyamashoko firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT tanimototakuya firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT shodahiroyasu firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport
AT ishikawanobuhisa firstlineimmunecheckpointtherapyinmetastaticsquamouscelllungcancerharboringbothegfrmutationandhighexpressionofpdl1acasereport

Ejemplares similares